Neurocrine Bio. (NBIX) PT Lowered to $107 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $146.24 +0.10%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 24 | New: 16
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 24 | New: 16
Join SI Premium – FREE
Wedbush analyst Laura Chico lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $107.00 (from $112.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
- Carter's (CRI) PT Lowered to $33 at UBS
- Estee Lauder (EL) PT Raised to $129 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
